Cloudbreak Pharma Inc. is a clinical-stage biotechnology company specializing in the development of ophthalmic drugs to address chronic eye diseases. Founded in 2015 and headquartered in Irvine, California, the company focuses on innovative treatments for conditions with limited therapeutic options, aiming to improve both vision and quality of life for patients. Cloudbreak Pharma’s diverse research and development team leverages deep expertise in ocular drug development, targeting mechanisms underlying various ophthalmic disorders.

A notable feature of Cloudbreak Pharma’s portfolio is its lead pipeline candidate, CBT-001, an investigational eye drop therapy designed to potentially slow or halt the progression of pterygium, a common eye condition. The company has entered multiple licensing agreements to facilitate commercialization and manufacturing of its products across major Asian markets. Beyond pterygium, Cloudbreak Pharma’s pipeline includes drug candidates for meibomian gland dysfunction, pinguecula, diabetic macular oedema, and presbyopia, illustrating a broad commitment to unmet needs in eye health. Through its research, Cloudbreak Pharma occupies a significant role in advancing ophthalmic therapeutics on a global scale.